Stockscreener 앱 받기
15.15
2.30%
0.34
시간 외 거래:
15.84
0.69
+4.55%
전일 마감가:
$14.81
열려 있는:
$14.65
하루 거래량:
1.68M
Relative Volume:
1.75
시가총액:
$1.53B
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-6.587
EPS:
-2.3
순현금흐름:
$-197.47M
1주 성능:
+5.57%
1개월 성능:
+7.45%
6개월 성능:
-11.76%
1년 성능:
+18.73%
1일 변동 폭
$14.43
$15.20
1주일 범위
$14.03
$16.23
52주 변동 폭
$10.90
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Upgraded by TD Cowen - MarketBeat
Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically - Simply Wall St
Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance
What is HC Wainwright's Estimate for DAWN Q1 Earnings? - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey
Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers - TipRanks
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Beats Estimates By $0.58 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - MarketBeat
Pre-Market Trading Boosts Day One (DAWN) Amid High OJEMDA Demand - Stocks Telegraph
Day One Biopharmaceuticals (NASDAQ:DAWN) Receives Buy Rating from HC Wainwright - MarketBeat
ChromaDex Q3 2024 Earnings Preview - MSN
Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates - MSN
Day One Biopharmaceuticals Reports Strong Q3 Growth - TipRanks
Day One Biopharmaceuticals earnings beat by $0.99, revenue topped estimates - Investing.com UK
DAWNDay One Biopharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - GlobeNewswire
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap UpStill a Buy? - MarketBeat
Day One Biopharma shares retain overweight rating on ojemda drug usage - Investing.com UK
Day One Biopharmaceuticals (DAWN) to Release Earnings on Wednesday - MarketBeat
Global Cancer Antibody Drug Conjugates Market Size Forecast 2030 - GlobeNewswire Inc.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet - Yahoo Finance
DAWN Q3 EPS Estimate Boosted by Capital One Financial - MarketBeat
How To Trade (DAWN) - Stock Traders Daily
Did Day One Biopharmaceuticals Inc (DAWN) perform well in the last session? - US Post News
Low Grade Glioma Market to Rise by 2034 | Day One - openPR
Day One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric Glioma - Insider Monkey
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 - GlobeNewswire
Day One Biopharmaceuticals Breaks Above 200-Day Moving AverageBullish for DAWN - Nasdaq
Day One Biopharmaceuticals Inc (DAWN) is looking forward to a strong quarter - SETE News
Recent Insider Activity Suggests Potential Gains for Day One Biopharmaceuticals Inc (DAWN) - Knox Daily
184,230 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Essex Investment Management Co. LLC - MarketBeat
The Significance of Moving Averages in Day One Biopharmaceuticals Inc Inc. (DAWN) Price Performance - The InvestChronicle
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Holdings Lifted by AQR Capital Management LLC - MarketBeat
Day One Biopharmaceuticals Inc [DAWN] Records 200-Day SMA of $14.60 - Knox Daily
A stock that deserves closer examination: Day One Biopharmaceuticals Inc (DAWN) - US Post News
Day One Biopharmaceuticals stock target raised, holds buy on Ojemda outlook - Investing.com Canada
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 5.2% Following Analyst Upgrade - MarketBeat
Needham & Company LLC Increases Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $33.00 - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trading Day Triumph: Day One Biopharmaceuticals Inc (DAWN) Ends at 13.58, a -3.69 Surge/Plunge - The Dwinnex
Day One Biopharmaceuticals Inc (DAWN) looking to reclaim success with recent performance - SETE News
Renaissance Technologies LLC Makes New Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 4.2% - MarketBeat
In the Green: Day One Biopharmaceuticals Inc (DAWN) Closes at 13.62, Up/Down -2.71 from Previous Day - The Dwinnex
What was Day One Biopharmaceuticals Inc (DAWN)’s performance in the last session? - US Post News
Day One Biopharmaceuticals Inc [DAWN] HEAD OF R&D makes an insider purchase of 30,000 shares worth 0.43 million. – Knox Daily - Knox Daily
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):